Aileron Therapeutics (NASDAQ: ALRN) spotted trading -87.07% off 52-week high price. On the other end, the stock has been noted 38.46% away from the low price over the last 52-weeks. The stock changed 0.00% to recent value of $0.72. The stock transacted 428879 shares during most recent day however it has an average volume of 164.65K shares. The company has 27.32M of outstanding shares and 15.35M shares were floated in the market.
Aileron Therapeutics (NASDAQ: ALRN) the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, reported that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ALRN-6924 as a myelopreservation agent in patients with p53-mutant cancers treated with chemotherapy.
We are excited to advance another application for ALRN-6924 into the clinic. In preclinical studies ALRN-6924 has been shown to trigger a transient, dose-dependent cell-cycle arrest in normal bone marrow cells with normal p53. As others have shown, triggering cell-cycle arrest in rapidly dividing normal cells, such as bone marrow cells, can protect them from toxic effects of chemotherapy. In the clinic we plan to use a precision medicine approach to treat patients with cancers harboring p53 mutations (approximately 50% of all cancers). ALRN-6924 does not induce cell-cycle arrest in p53-mutant cancer cells, and leaves them vulnerable to chemotherapy. While our first myelopreservation clinical trial will be in small cell lung cancer patients treated with topotecan, we plan to develop ALRN-6924 as a tumor type-agnostic myelopreservation drug, stated Dr. Vojislav Vukovic, Chief Medical Officer of Aileron.
The FDA acceptance of our IND application represents an important milestone for ALRN-6924 and keeps us on schedule to commence our first clinical trial in myelopreservation as planned in September 2019, said Dr. Manuel Aivado CEO & President of Aileron. Chemotherapy remains the standard of care for many cancer patients, yet it damages the bone marrow and other normal cells, causing serious and often life-threatening side effects for patients. With ALRN-6924, we are exploring the potential to protect normal cells and improve the outcome of patients with p53-mutated cancers without diminishing anti-tumor activity, regardless of the type of chemotherapy. We are very excited about the possibility to spare cancer patients from chemotherapy-induced toxicities. Its earnings per share (EPS) expected to touch remained -39.20% for this year while earning per share for the next 5-years is expected to reach at 2.10%. According to the most recent quarter its current ratio was 3.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of -17.87% from the mean of 20 days, -40.84% from mean of 50 days SMA and performed -58.26% from mean of 200 days price. Company’s performance for the week was -12.20%, -27.94% for month and YTD performance remained -14.29%.
Adam Benton also covers the financial news across all market sectors. He also has an enormous knowledge of stock market. He holds an MBA degree from University of Indiana. He has more than 10 years of experience in writing financial and market news. Adam previously worked at a number of companies in different role including web developer, software engineer and product manager. He currently covers financial news section for our site.
Address: 3063 Charack Road, Bedford, Indiana
Phone number: 812-278-8610